Back

SGLT2-inhibitors and iron status in heart failure

21 January 2025 (15:22 - 15:45)
Organised by: Logo
Seminar Presentation Part of: The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart Drugs, Drug Targets Delegate Premium access HFA Winter Research Meeting on Translational Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Julio Nunez Villota

Instituto de Investigacion Sanitaria INCLIVA, Valencia (Spain)

3 More presentations in this session

Presentation thumbnail
Off target effects of SGLT2-inhibitors
Assistant Professor C. Zuurbier (Amsterdam, NL)
Presentation thumbnail
Metabolic alterations and post-translational modifications in the failing heart
Professor L. Bertrand (Brussels, BE)
Slides
Presentation thumbnail
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Professor R. De Boer (Rotterdam, NL)
Slides

Access the full session

Session thumbnail
The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart

The Event

Event poster

HFA Winter Research Meeting on Translational Heart Failure 2025

21 January 2025 15:22 CET
You may be interested in
thumbnail
Congress Session
Moving targets of treatment in heart failure
20 May 2025
thumbnail
Congress Presentation
Safety of SGLT2-Inhibitors in cardio-oncology patients with heart failure undergoing cancer treatment
21 June 2025
thumbnail
Congress Presentation
Trace element equilibrium in acute heart failure and the effect of empagliflozin
20 May 2023
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources